This week's FierceLifeSci is brought to you by the FierceBiotech Drug Development Forum. |
Register today to hear from 70+ biotech industry leading speakers. | | | Dear Colleague, At a time of unprecedented regulatory and financial challenges, the FierceBiotech 2nd Drug Development Forum, taking place September 25-27, 2017 in Boston, MA, is the biotech industry’s unique venue for executive-level problem-solving. With an all-new agenda built from audience feedback, this event goes into unprecedented detail on the greatest partnership challenges that biotech companies face throughout the entire product and corporate development cycle! Hear from 70+ biotech industry leading speakers, including: | | Edward Kaye, CEO, SAREPTA THERAPEUTICS |
| | Cynthia Schwalm, President, North American Commercial Operations, IPSEN |
| | Richard Gregory, CSO, IMMUNOGEN |
| | Sara Nochur, Senior Vice President, Regulatory Affairs, ALNYLAM PHARMACEUTICALS |
| | Angus Grant, Vice President, Regulatory Affairs, Finance, CELGENE |
| | Pablo Lapuerta, CMO, LEXICON PHARMACEUTICALS |
| | Michael Bailey, CEO, AVEO ONCOLOGY |
| | Bryon Wornson, Vice President, Global Health and Value, PFIZER |
| | Chandra Ramanathan, Vice President, Head, East Coast Innovation Center, BAYER |
| | Tehseen Salimi, Vice President, Medical Affairs, TREVENA |
| | Roy Baynes, Senior Vice President, Head of Clinical Development , MERCK |
| | Shakti Narayan, Vice President, Head of Transactions, JOHNSON & JOHNSON |
|
| This year’s conference also features: Three full days, four workshops and four tracks 10+ hours of networking with 350+ attendees In-depth insight on the industry’s biggest challenges, delivered through sessions such as: Make Advances in a Hyper-Competitive Immuno-Oncology Market Industry Strategy on Drug Pricing Ensure that Innovative Companies Are Rewarded for Taking Risks Maintain Flexibility, Creativity and Independence in Partnerships Between Large and Small Biotechs Aim for Success in a Highly Partnered Business Model Secure Funding for Preclinical Companies Shorten the Path from Preclinical to Clinical Phases Pioneer Novel Deal Structures in a Changing Marketplace | Register today and do not miss out on this one-of-a-kind learning and networking experience! Advance conference rates expire Friday, June 30. I look forward to welcoming you to Boston this fall! Sincerely,
| Matt Greenbaum Production Team Leader ExL Events, a Division of Questex, LLC | Rebecca Willumson Publisher FierceBiotech |
| SPONSORED BY: | | For information on sponsorship and exhibition opportunities, please contact Andrew Sinetar at [email protected] or 212-400-6237 | Forward this email to a colleague Copyright © 2017 ExL Events, All rights reserved. 494 8th Avenue, 4th Floor, New York, NY 10001 Phone: 212-400-6240 Email: [email protected]
|
|
Reach 300,000+ subscribers with your own message. Contact Angelique Alcover at [email protected] or call 202-824-5074.
About this email: In order to receive FierceLifeSci for free, we ask that you accept an occasional email promotion from our sponsors. We carefully screen each promotion and never sell or give away your personal information. If you do not want to receive these messages, you can unsubscribe entirely from FierceLifeSci . [Click here] to unsubscribe. FierceMarkets, a division of Questex, LLC 1900 L St. NW Suite 400 Washington, DC 20036 |
|